

GENMAB LICENSES CANCER TARGET FROM GANYMED

Conference Call

Genmab's Management will hold a conference call to discuss the news today, Monday, April 26, at

4:00 pm CET

3:00 pm GMT

10:00 am US Eastern Time

The dial in numbers are as follows:

+1-800-915-4836 (in the US) and ask for the Genmab conference call

+1-973-317-5319 (outside the US) and ask for the Genmab conference call

The conference call will be held in English.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAB(tm) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit www.genmab.com.

About Ganymed Pharmaceuticals AG

Ganymed Pharmaceuticals AG creates products based on highly selective disease-specific antigens as targets for therapeutics and diagnostics. Ganymed's vision is to enable a new era in the treatment of cancer and other life threatening diseases with unsatisfied medical need by developing well-tolerated potent pharmaceuticals that exclusively target diseased cells thus sparing healthy tissues. Using its Virtual cloning, Membranomics™, cancer splice variant screen and MicroGATE™ technologies, Ganymed is establishing a broad patent portfolio for target structures selectively expressed in frequent cancers including cancer of lung, breast, colon, pancreas, stomach, ovary and prostate. Ganymed's dual business strategy generates early income by outlicensing identified antigens and creates value by developing strategic alliances with leading biotech or pharmaceutical companies. This strategy is expected to provide both the chance to become a fully integrated pharmaceutical company as well as the flexibility for a permanent alliance with leading world-wide pharmaceutical partners.

GENMAB LICENSES CANCER TARGET FROM GANYMED

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects.

Statements that are not historical facts, including statements preceded by, followed by, or that include the words “believes”; “anticipates”; “plans”; “expects”; “estimates”; or similar statements are forward-looking statements. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

###